MAPT and Alzheimer disease: A fluid-based biomarker with sufficient sensitivity and specificity to be of practical use for identifying CTE is essential, a combined CSF p-tau 231/ Aβ 1-42 assay has shown promise distinguishing CTE from AD but limited to postmortem samples (75).